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ABSTRACT 
Orbital and pretibial fibroblasts are targets of autoimmune attack 
in Graves’ ophthalmopathy (GO) and pretibial dermopathy (PTD). 
The fibroblast autoantigen involved in these peripheral manifestations 
of Graves’ disease and the reason for the association of GO and PTD 
with hyperthyroidism are unknown. RNA encoding the full-length 
extracellular domain of the TSH receptor has been demonstrated in 
orbital and dermal fibroblasts from patients with GO and normal 
subjects, suggesting a possible antigenic link between fibroblasts and 
thyrocytes. 
RNA was isolated from cultured orbital, pretibial, and abdominal 
fibroblasts obtained from patients with severe GO (n = 22) and normal 
subjects (n = 5). RNA was reverse transcribed, and the resulting cDNA 
was amplified by the polymerase chain reaction, using primers spanning 
overlapping regions of the entire extracellular domain of the TSH 
receptor. Nucleotide sequence analysis showed an A for C substitution 
in the first position of codon 52 in 2 of the patients, both of whom had 
GO, PTD, and acropachy. Genomic DNA isolated from the 2 affected 
patients, and not from an additional 12 normal subjects, revealed the 
codon 52 mutation by direct sequencing and AciI restriction enzyme 
digestions. 
In conclusion, we have demonstrated the uresence of a eenomic 
point mutation, leading to a threonine for pro&e amino acid-shift in 
the predicted peptide, in the extracellular domain of the TSH receptor 
in two patients with severe GO, PTD, acropachy, and high thyroid- 
stimulating immunoglobulin levels. RNA encoding this mutant product 
was demonstrated in the fibroblasts of these patients. We suggest that 
the TSH receptor may be an important fibroblast autoantigen in GO 
and PTD, and that this mutant form of the receptor may have unique 
immunogenic properties. (J Clin Endocrind Metab 78: 256-260,1994) 
0 RBITAL and pretibial fibroblasts are targets of autoim- mune attack in Graves’ ophthalmopathy (GO) and 
pretibial dermopathy (PTD) (1). However, the association of 
the hyperthyroidism of Graves’ disease with these connective 
tissue-based extrathyroidal manifestations has long been 
enigmatic. We have shown previously that fibroblasts con- 
tain RNA encoding the extracellular domain of the TSH 
receptor (2). Similar findings (in retroorbital tissue samples) 
have been reported by another group (3). If translated into 
protein, this fibroblast autoantigen might be recognized by 
lymphocytes directed against the TSH receptor in Graves’ 
disease. The subsequent infiltration of the orbit and skin by 
activated cytokine-producing lymphocytes would probably 
stimulate glycosaminoglycan synthesis and proliferation of 
the resident fibroblasts (1). The resulting histological changes 
would be those characteristic of the involved tissues in GO 
and PTD (4). 
Autoantigens are expected to be normal in autoimmune 
diseases; the abnormality is most likely to be found in the 
immune system itself. However, a somatic point mutation in 
the extracellular domain of the TSH receptor has been re- 
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ported in thyroid RNA of a patient with Graves’ disease (5). 
As the somatic mutation is located in a putative ligand- 
binding domain, the researchers speculated that the mutation 
has a causal relationship to the patient’s thyroid disorder. 
We wished to determine whether there might be a mutation 
in the TSH receptor gene in fibroblasts of patients with GO. 
In this study we demonstrate a genomic point mutation in 
the extracellular domain of the TSH receptor in two patients 
with GO, PTD, acropachy, and high thyroid-stimulating 
immunoglobulin (TSI) levels. RNA encoding the product of 
this mutant gene is present in fibroblasts from these patients. 
Because of the high levels of antibody activity directed 
against the TSH receptor in these two patients and the 
severity of their connective tissue manifestations, we hypoth- 
esize that the protein product of their mutant TSH receptor 
gene may have unique immunogenic properties. 
Materials and Methods 
Subjects 
Orbital connective tissue was obtained from patients with severe GO 
(n = 22) in the course of transantral orbital decompression surgery (see 
Table 1 for clinical details). Normal orbital connective tissue was ob- 
tained from individuals with no history of thyroid disease who under- 
went orbital surgery for unrelated conditions (n = 5). Pretibial (n = 2) 
and abdominal (n = 1) skin biopsies were obtained by written consent 
and Institutional Review Board approval from two of the patients with 
GO who also had PTD (patients 1 and 18; Table 1). In addition, a fine 
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TABLE 1. Clinical characteristics and TSH receptor analysis in 22 
patients with severe GO 
Patient Age Presence of Presence of TSI 
Presence of 
no. (Yd Sex PTD acropschy index” 
codon 52 
mutation 
1 39 
2 67 
3 34 
4 34 
5 58 
6 50 
7 65 
8 55 
9 85 
10 55 
11 45 
12 68 
13 64 
14 62 
15 45 
16 63 
17 53 
18 55 
19 51 
20 54 
21 61 
22 50 
F + 
F - 
F” 
- 
+ 
F 
+ 
+ 
F - 
+ 
5 - 
M - 
F - 
iti - 
F - 
F - 
- 
F - 
+ 
F” - 
- 
L - 
F + 
+ 16 + 
- ND* - 
8.9 - 
1.9 - 
+ ND - 
+ 22 + 
- ND - 
19 - 
ND - 
- 8.4 - 
13 
17 
9.4 - 
- 8.7 - 
- 18 - 
- 14 - 
- 8.7 - 
- 17 - 
8.8 - 
- 5.7 - 
6.4 - 
+ 15 - 
a TSI index at time of orbital decompression surgery (normal = O.O- 
1.3). 
* Not done. 
needle aspiration biopsy of the thyroid was obtained from patient 1. 
Peripheral blood samples were collected from additional patients with 
severe GO (n = 3) and normal subjects (n = 12). Peripheral blood 
mononuclear cells (PBMC) were isolated from whole blood using stand- 
ard procedures (6). Serum TSI activity was determined using a standard 
assay that measures CAMP generation in cultured FRTL-5 thyroid cells 
(7). 
Cell culture 
Fibroblast cultures were established from biopsy specimens, as de- 
scribed previously (8). Briefly, tissue explants were minced and placed 
directly on plastic culture dishes, and fibroblasts were allowed to prolif- 
erate. Fibroblast cultures were propagated in medium 199 containing 
20% fetal bovine serum (HyClone Laboratories, Logan, UT), penicillin 
(100 IU/mL), and gentamycin (20 rg/mL) in a humidified 5% CO1 
incubator at 37 C. All cell cultures established in this fashion stain 
positively for a specific antifibroblast antigen (Dakopatts Corp., Santa 
Barbara, CA). Cultures were maintained in 75-mm2 flasks with medium 
199 containing 10% fetal bovine serum and were used between the first 
and fifth passages. Cultured Chinese hamster ovary (CHO) cells, trans- 
fected with either plasmid containing the human TSH receptor (Jr09 
line) or the untransfected counterpart (Jr02 line) (9), and Fisher rat 
thyroid cells (FRTL-5, CRL 8305, American Type Culture Collection, 
Rockville, MD) were used as control cell lines. 
RNA/DNA amplification with transcript sequencing 
Total RNA was isolated directly from 1 X lo6 fibroblast cells using 
guanidinium thiocyanate and cesium chloride (10). First strand cDNA 
synthesis was performed using 20 pg heat-denatured total RNA and 
random hexamers (11). The resulting cDNA was amplified by the 
polymerase chain reaction (PCR) with primers spanning overlapping 
regions of the entire extracellular domain of the TSH receptor. Oligo- 
nucleotide primers 2 and 3 were used for amplification of the cDNA 
fragment containing the base pair (bp) substitution (Table 2). PCR 
amplification was performed with 4 pL cDNA template and 5.0 pmol of 
each PCR primer in 10 mmol Tris-HCl (pH 8.3), 50 mmol KCl, 1.5 mmol 
MgC&, 200 pmol/L of each deoxy-NTP, and 1 LJ Ampli-Taq DNA 
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TABLE 2. Oligonucleotide sequences and descriptions of primers 
Primer 
no. 
Oligonucleotide sequence Description” 
1 5’-TAATACGACTCACTATAG- Residues 90-108: 
GGAGATCCCGTGGAAAAT- sense strand* 
GAGGCC-3’ 
2 5’-ATTTAGGTGACACTATAG- Residues -90-108: 
AATACTCCCGTGGAAAAT- sense strand 
GAGGCC-3’ 
3 5’-TAATACGACTCACTATAG- Residues 854-873: 
GGAGACAGGTGTTTCTTG- antisense strand 
CTATCAG-3’ 
4 5’-TAATACGACTCACTATAG- Residues 299-316: 
GGAGAAAATGCATGACTT- antisense 
GGAAT-3’ strand* 
5 5’-CATACACATACGATTTAG- Residues 255-270: 
GTGACACTATAGAATACA- antisense 
GAGTCTGCGTACTGG-3’ strandd 
a Nucleotide positions are according to Nagayama et al. (12). 
* T7 phage promoter as first 23 nucleotides. 
‘Sp6 phage promoter as first 23 nucleotides. 
d Sp6 phage promoter as first 35 nucleotides. 
polymerase (Perkin-Elmer/Cetus, Norwalk, CT) in a final volume of 50 
pL. The amplification reaction for cDNA was 35 cycles (Perkin-Elmer 
thermal cycler 801-0150); each cycle consisted of 94 C for 1 min 
(denaturation), 55 C for 2 min (annealing), and 72 C for 3 min (elon- 
gation), followed by a final lo-min extension at 72 C. 
Genomic DNA was isolated and purified from 1 X lo5 fibroblasts or 
PBMC from 7 mL whole blood by standard procedures (6). In addition, 
genomic DNA was isolated from cells obtained by a thyroid fine needle 
aspiration and digested with proteinase-K (12). The procedure for am- 
plification of genomic DNA was identical to that described above, except 
that 1 pL DNA and PCR primers 1 and 5 (Table 2; 2.5 pmol each) were 
amplified using 0.5 U Ampli-Taq polymerase in a total volume of 20 pL; 
the annealing temperature was 55 C. For the thyroid fine needle aspi- 
ration sample, 20 pL cell lysate were amplified with PCR primers 2 and 
4 (50 pmol each) and 2 U Ampli-Taq DNA polymerase in a total volume 
of 80 rL; 4 rL of this product were reamplified with primers 1 and 5 
(10 pmol each) and 1 U Ampli-Taq DNA polymerase in a total volume 
of 50 rL. Amplification reaction conditions were the same as described 
above. 
For direct sequencing of amplified segments from cDNA or genomic 
DNA, 3 rL of the amplified material were added to 17 rL transcription 
mixture [40 mmol/L Tris-HCl (pH 7.5), 6 mrnol/L MgCl,, 2 mmol/L 
spermidine, 10 mmol/L NaCl, 0.5 mmol/L of each ribonucleoside tri- 
phosphate, 1.6 IJ/mL RNasin, 10 mmol/L dithiothreitol (DTT), 10 U T7 
RNA polymerase, and diethylpyrocarbonate-treated H,O] (13). Samples 
were incubated for 1 h at 37 C, and the reaction was stopped by heating 
at 65 C for 10 min. A 2-rL aliquot of the transcription reaction was 
added to 10 rL annealing buffer (250 mmol/L KC1 and 10 mmol/L Tris- 
HCl, pH 8.3) containing a 3zP end-labeled reverse transcription primer. 
Samples were heated at 80 C for 3 min and then annealed for 45 min 
at 45 C. A 2-pL aliquot of the primer RNA template solution was added 
to 3.3 PL reverse transcriptase buffer [24 mmol/L Tris-HCl (pH 8.3), 16 
mmol/L MgCl,, 8 mmol/L DTT, 0.4 mmol/L of each deoxyribonucleo- 
side triphosphate, and 0.4 mmol/L thymidine triphosphate] containing 
5 U avian myeloma virus reverse transcriptase and 1 PL of a dideoxyri- 
bonucleoside triphosphate. The sample was incubated at 50 C for 45 
min, and the reaction was stopped by adding 2.5 pL formamide (100%) 
with bromophenol blue (0.3%) and xylene cyan01 FF. Samples were 
boiled for 3 min, and a 1.5-rL aliquot was loaded onto a 100~cm 
sequencing gel and separated by electrophoresis (-15,000 V-h). Auto- 
radiography was performed, and gels were read manually. 
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Restriction enzyme digestions 
Each cDNA amplification product (20 wL) was digested at 37 C 
overnight in 1 X NEB buffer 3*(100 mm01 NaCl, 50 mmol Tris-HCl, 10 
mm01 MaCb and 1 mm01 DTT, uH 7.9. at 25 C) with 15 U AciI enzvme 
(551S, Ne&. England Biolabs,’ inc., Beverly, MA) in a total reaction 
volume of 30 pL. Digestion products (15 wL) were resolved on 2% 
agarose gels (wild-type cDNA produces fragments of 44, 49, 92, and 
642 bp; mutant cDNA produces fragments of 734, 44, and 49 bp; 
undigested cDNA fragment is 827 bp). The digestion of the amplified 
product from genomic DNA was identical, except that each amplification 
product (10 ILL) was digested with 10 U AciI enzyme in a total reaction 
volume of 20 PL that was entirely loaded onto a 4% agarose gel 
(fragments from wild-type DNA are 44,49,55, and 92 bp; mutant DNA 
produces fragments of 146,44, and 49 bp; undigested DNA fragment is 
240 bp). 
Results 
For the PCR-based amplification of TSH receptor RNA, 
primers were designed to amplify overlapping fragments of 
cDNA encompassing the full-length extracellular domain of 
the TSH receptor. The entire 1183-bp extracellular domain 
was sequenced using RNA derived from cultured retroocular 
fibroblasts obtained from 22 patients with GO and 5 normal 
subjects and from cultured pretibial (n = 2) and abdominal 
(n = 1) skin fibroblasts from 2 of the patients with GO who 
also had PTD (patients 1 and 18; Table 1). In each sample, 
we found nucleotide sequence corresponding to the full- 
length extracellular domain reported by Nagayama et al. 
(14), except for an A for C substitution in the first position 
of codon 52 that was present in fibroblast RNA samples 
from 2 of the patients studied (patients 1 and 6; Fig. 1). The 
wild-type receptor sequence (CCC at codon 52) was also 
present in each of these 2 samples. The reverse transcription 
step and cDNA amplification were repeated several times 
with identical results in both of these patients. The presence 
of the mutation was subsequently verified in RNA from both 
patients using AciI restriction enzyme digestions of amplified 
cDNA (Fig. 2). This mutation leads to a threonine for proline 
amino acid shift in the predicted peptide. Proline, the wild- 
type amino acid at codon 52, is highly conserved; its presence 
in this position has been demonstrated in both the rat (15) 
and dog (16) TSH receptor sequences. 
To determine whether the mutation in codon 52 of the 
TSH receptor is a germline mutation, we examined genomic 
DNA from patients 1 and 6 (Table 1). AciI restriction enzyme 
digestions of amplified genomic DNA from patient 1 dem- 
onstrated both the wild-type and the mutant nucleotide 
sequences at the first position of codon 52 in cultured retro- 
ocular, pretibial skin, and abdominal skin fibroblasts; cells 
ATGC 
m Wl 
FIG. 1. Sequence analysis of the two forms of TSH receptor. Amplified 
PCR fragments from cDNA template were sequenced as described in 
Materials and Methods. The wild-type (wt) form has a cystine at the 
first position of codon 52 (noted by markers; right). The mutant (m) 
form (cDNA template was derived from uatient 1) has both a cvstine 
and an adenine at this position (left). - 
1234567891011 
FIG. 2. AciI restriction enzyme digestions of PCR fragments amplified 
from cDNA templates. The undigested fragment size is 827 bp. AciI 
digestion of wild-type sequence produces 642-, 92-, 49-, and 44-bp 
fragments; the mutant allele produces an additional 734-bp fragment. 
Derivation of cDNA templates in lanes following the 106-bp ladder is 
as follows: 1) JPO9 (TSH receptor-positive CHO cells; undigested), 2) 
patient 1 (undigested), 3) JPO9, 4) patient 1 orbital tibroblasts, 5) 
patient 1 pretibial skin tibroblasts, 6) patient 1 abdominal skin fibro- 
blasts, 7) orbital fibroblasts from a normal subject, 8) patient 6 orbital 
tibroblasts, 9) rat thyroid cells (FRTL-5), 10) JP02 (TSH receptor- 
negative CHO cells), and 11) patient 8 orbital fibroblasts. 
1234567 
FIG. 3. AciI restriction enzyme digestions of PCR fragments amplified 
from genomic DNA template from patient 1. The undigested fragment 
is 240 bp. AciI digestion of wild-type sequence produces fragments of 
44, 50, 54, and 92 bp; the mutant allele produces an additional 146-bp 
band. Derivation of genomic DNA templates in lanes following the 
lOO-bp ladder are as follows: 1) patient 1 orbital fibroblasts (undig- 
ested), 2) orbital tibroblasts from a normal subject, 3) patient 1 orbital 
fibroblasts, 4) patient 1 pretibial fibroblasts, 5) patient 1 abdominal 
fibroblasts, 6) patient 1 thyroid fine needle aspiration sample, and 7) 
patient 1 PBMC. 
from a thyroid fine needle aspiration sample; and PBMC 
(Fig. 3). The reproducible findings of the mutation in cells 
from several sites obtained from the same patient and its 
consistent heterozygosity, mitigate strongly against a Tu9 
polymerase error being responsible for these results. 
The same restriction enzyme digestion strategy was used 
to examine genomic DNA from PBMC of 12 normal subjects. 
None was found to have the mutation at codon 52. These 
12 normal subjects, in addition to the 5 normal subjects 
whose fibroblast RNA was entirely sequenced in the area of 
codon 52, bring to a total of 17 the normal subjects studied; 
none had the mutation. 
In addition to the mutation in the first position of codon 
52, we observed a polymorphism at nucleotide position 661 
(third position of codon 187). We found 13 of 22 patients 
with GO to be homozygous for thymidine at this position, 1 
GO patient was homozygous for cytosine, and the remaining 
GO patients were heterozygous (thymidine/cytosine) at 661. 
Four of the normal subjects were homozygous for thymidine 
at nucleotide position 661; the remaining normal subject was 
heterozygous (thymidine/cytosine). We consider this varia- 
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tion, found in both normal individuals and GO patients, to 
be a polymorphism because it would not result in a change 
in the wild-type amino acid (asparagine) at codon 187. 
Discussion 
We report the presence of a germline mutation in the first 
position of codon 52 of the TSH receptor in two patients 
with severe GO, PTD, acropachy, and high TSI levels. Sev- 
eral groups of investigators have identified regions on the 
N-terminal region of the extracellular domain of the TSH 
receptor that appear to have epitopes for binding of TSH or 
antibodies directed against this receptor. Amino acid residues 
30-33, 34-37, 42-45, 52-56, and 58-61 (17); 32-56 (18); 
and 38-45 (19) have been specifically implicated as impor- 
tant stimulatory antibody-binding regions. However, it is 
likely that these epitopes are conformational and include 
multiple discontinuous regions spanning the entire extracel- 
lular domain (19), and perhaps the extracellular loops of the 
transmembrane domains, of the TSH receptor (18-21). The 
mutation described in our study would lead to a threonine 
for proline shift in amino acid residue 52. It is possible that 
the substitution of threonine (a neutral and polar amino acid) 
for proline (a neutral and hydrophobic amino acid) would 
result in a conformational change in the extracellular portion 
of the TSH receptor. Such a change could alter the immu- 
nogenicity or function of this protein. 
The finding of mRNA for the TSH receptor in fibroblasts 
using PCR does not guarantee the presence of functional or 
immunologically active TSH receptor protein in these cells. 
Indirect evidence for the presence of this receptor on fibro- 
blasts is suggested by our finding of enhanced expression of 
adhesion molecules (22) and a 72-kilodalton heat shock 
protein (23) after treatment of human retroocular fibroblast 
cultures with immunoglobulin G derived from patients with 
GO and high TSI levels, More direct evidence has been 
forwarded by Burch and colleagues (24), who demonstrated 
binding of polyclonal rabbit antiserum directed against a 
TSH receptor peptide (amino acid residues 352-367) in cul- 
tured retroocular fibroblasts. Reversible low affinity binding 
of [lz51]bovine TSH has been detected on porcine orbital 
connective tissue membranes (25). 
Acropachy is a rare connective tissue manifestation of 
Graves’ disease. Clinical features include drumstick clubbing 
of the digits, reticular subperiosteal new bone formation, and 
soft tissue swelling that is similar histologically to that seen 
in pretibial skin in PTD (4). In most instances, the peripheral 
manifestations of Graves’ disease develop in hierarchy; GO 
is the first presentation, PTD develops next, and finally, 
acropachy may occur when the disease is quite prolonged or 
intense. It is of interest that both patients found to have the 
codon 52 mutation also have PTD and acropachy. In addi- 
tion, these patients had among the highest TSI levels meas- 
ured in our study. We hypothesize that these two patients 
may have a particularly intense autoimmune response di- 
rected against their TSH receptor, leading to the high TSI 
levels and remarkable clinical features. It may be that their 
mutant form of the TSH receptor is particularly immuno- 
genic. 
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This is the first report, to our knowledge, of a germline 
mutation in the TSH receptor. Point mutations causing amino 
acid substitutions in membrane proteins have been causally 
implicated in the pathogenesis of autosomal dominant dis- 
eases, including Charcot-Marie-Tooth disease type IA (26) 
and hyperkalemic periodic paralysis (27). In the latter disease, 
mutations affecting transmembrane domains of a skeletal 
muscle sodium channel gene product have been identified, 
the presence of which presumably alters sodium channel 
properties leading to the disease. However, the mechanism 
by which a point mutation with a resulting amino acid 
substitution might lead to an autoimmune disease is unclear, 
and there exists no precedent in other autoimmune diseases. 
Although various HLA-DR antigens (especially HLA-DR3) 
are associated with GO (28), no particular gene has been 
shown to confer strong susceptibility for the condition. Evi- 
dence suggests that a permissive genetic background, in 
addition to the presence of certain environmental factors, 
may be necessary for the full clinical expression of GO in 
patients with Graves’ disease. It may be that the presence of 
the codon 52 mutation along with particular HLA haplotypes 
and environmental factors leads to an especially intense 
autoimmune reaction directed against TSH receptors. This 
reaction may be appreciated clinically as severe connective 
tissue involvement in Graves’ disease. It is of note that 
neither of the patients found to have the mutation related a 
family history of thyroid disease. Further, two of the patients 
studied (patients 5 and 22) had PTD and acropachy, but did 
not have a TSH receptor extracellular domain mutation. 
Perhaps the codon 52 mutation is only one of several per- 
missive factors involved in the development of the severe 
connective tissue manifestations of Graves’ disease. An un- 
derstanding of the potential pathogenic importance of this 
mutation awaits further study. 
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27th Annual Meeting Society for the Study of Reproduction 
July 24-27,1994 
University of Michigan, Ann Arbor, Michigan 
The 27th Annual Meeting of the Society for the Study of Reproduction will include a symposium on 
regulation of testicular and epididymal function. Michael Griswold, Anita Payne, and Bernard Robaire will 
be speakers. State-of-the-art lectures will feature the use of microdialysis in the study of reproductive 
mechanisms and implementing transgenic and embryonic stem cell technology to study gene expression and 
function and cell-cell interactions. Speakers will be Jane Robinson and Sally Camper. Deadline for 
submission of abstracts for poster and platform presentations is February 15, 1994. For additional 
information and abstract forms, contact Judith Jansen, Executive Secretary, SSR, 1526 Jefferson Street, 
Madison, WI 53711-2106. Telephone: 608-256-2777; FAX: 608-256-4610. 
